BioRestorative Therapies (BRTX)

• Market cap: $10.2M
• 1 day: -3.76%
• 5 days: -3.03%
• 1 month: -19.5%
• 3 months: -16.88%
• 6 months: -19.5%
• Year to date: -14.09%
• 1 year: -5.88%
• 5 years: -81.77%
• 10 years: -81.77%
• Sector: Healthcare
• Industry: Biotechnology

About: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Employees: 11